Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Basal ganglia, cerebral cortex and subcortical white matter were studied for glial fibrillary acidic protein (GFAP) in four cases of hepatic encephalopathy (HE) with Alzheimer II gliosis and five age-matched controls. GFAP was measured by enzyme-linked immunosorbent assay (ELISA) and reflectance densitometry of immunoperoxidase-stained western blots. Both methods revealed a 70% decrease in the average amount of GFAP in the cerebral cortex and a 60% decrease in the basal ganglia in HE cases. GFAP in white matter was not significantly changed. In contrast to GFAP, the average protein content was not significantly different for HE and controls. These findings support the view that HE is a neurological disease in which there is a selective loss of GFAP from the grey matter.

What this study adds

Evidence grade: Low

In four cases of hepatic encephalopathy, GFAP was decreased by about 70% in the cerebral cortex and 60% in the basal ganglia compared with controls, while white matter GFAP was not significantly changed. This concerns hepatic encephalopathy, not Alzheimer's disease, so it does not directly inform Alzheimer's treatment or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kretzschmar, H. A., DeArmond, S. J., & Forno, L. S. (1985). Measurement of GFAP in hepatic encephalopathy by ELISA and transblots. Journal of neuropathology and experimental neurology. https://doi.org/10.1097/00005072-198509000-00002

Vancouver

Kretzschmar HA, DeArmond SJ, Forno LS. Measurement of GFAP in hepatic encephalopathy by ELISA and transblots. Journal of neuropathology and experimental neurology. 1985. doi:10.1097/00005072-198509000-00002. PMID: 3897466.

BibTeX

@article{kretzschmar1985-3897466,
  author  = {Kretzschmar, H. A. and DeArmond, S. J. and Forno, L. S.},
  title   = {{Measurement of GFAP in hepatic encephalopathy by ELISA and transblots}},
  journal = {Journal of neuropathology and experimental neurology},
  year    = {1985},
  doi     = {10.1097/00005072-198509000-00002},
  pmid    = {3897466},
  url     = {https://doi.org/10.1097/00005072-198509000-00002}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In four cases of hepatic encephalopathy, GFAP was decreased by about 70% in the cerebral cortex and 60% in the basal ganglia compared with controls, while white matter GFAP was not significantly changed. This concerns hepatic encephalopathy, not Alzheimer's disease, so it does not directly inform Alzheimer's treatment or prevention.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 38 of 100.38 of 100 points earned62 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of neuropathology and experimental neurology)
Journal's citation record 2 / 4 Journal of Neuropathology & Experimental Neurology: journal h-index 239 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1985 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 60 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.4 citations a year over 43 year(s) since 1985
Impact for its field and year 3 / 6 Cited 4.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Lysia S. Forno: h-index 46 (OpenAlex, whole career)
Institution's track record 3 / 3 Stanford University: institution h-index 2,684 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 3897466)
Free to read 0 / 2 Behind a paywall — scores zero
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →